Andrew Armstrong

Dec 11, 2024 | nature.com | Todd P. Knutson |Bin Luo |Michael Morris |Himisha Beltran |Emmanuel S. Antonarakis |Andrew Armstrong | +1 more

AbstractCirculating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant prostate cancer (mCRPC), ctDNA assays are needed to prognosticate outcomes of patients treated with androgen receptor (AR) inhibitors.

Sep 30, 2024 | nature.com | Andrew Armstrong |Scott T. Tagawa |Anthony Serritella

AbstractUnfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer. In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC.

Sep 26, 2024 | nature.com | Anthony Serritella |Scott T. Tagawa |Andrew Armstrong

AbstractUnfortunately, not all metastatic castration-resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing for prostate cancer. In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC.

May 22, 2024 | europeanurology.com | Adam B. Weiner |Andrew Armstrong |Alberto Bossi |La Garenne Colombes |Philip Cornford |Felix Feng | +9 more

Abstract Biochemical recurrence (BCR) after primary definitive treatment for prostate cancer (PCa) is a heterogeneous disease state. While BCR is associated with worse oncologic outcomes, risk factors that impact outcomes can vary significantly, necessitating avenues for risk stratification. We sought to identify prognostic risk factors at the time of recurrence after primary radical prostatectomy or radiotherapy, and prior to salvage treatment(s), associated with adverse oncologic outcomes.

Feb 11, 2024 | nature.com | Himisha Beltran |Michael Morris |Daniel George |Andrew Armstrong

AbstractCALGB 90401 (Alliance) was a phase III trial of 1050 patients with metastatic castration-resistant prostate cancer (mCRPC) comparing docetaxel, prednisone, bevacizumab (DP+B) versus DP alone. While this trial did not show an improvement in overall survival (OS), there were improved intermediate outcomes suggesting that subsets of men may derive benefit from this combination.